Publications

Posters & Presentations

CAL101

• 2025 November – PFF Summit poster: AURORA – A Global Phase 2 Study of CAL101

• 2025 November – PFF Summit poster: Evaluating the Safety, Tolerability and Pharmacokinetics of CAL101

• 2025 May – ATS poster: Therapeutic Potential of CAL101: A S100A4 Neutralizing Antibody for Fibrotic and Inflammatory Pulmonary Diseases

• 2025 May – ATS poster: Evaluating the Safety, Tolerability and Target Engagement Profile of CAL101, A Novel S100A4 Neutralizing Antibody, for Progression into Idiopathic Pulmonary Fibrosis

CAL103

• 2025 July – Immunology Summit presentation: Antibodies that neutralise oxidised phospholipids (OxPL) – a novel approach to RA

• 2025 May – ATS poster: Anti-OXPLAntibodies Modulates Pathways Driving COPD Pathophysiology

Articles

CAL101

• 2025 October: Development of CAL101—a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling. Signe Vedel Borchert, Jonas Hallén, Rizwan Iqbal Hussain, Ian Holyer, Jesper T. Troelsen, Jörg Klingelhöfer

• 2024 May: Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Thuong Trinh-Minh, Andrea-Hermina Györfi, Michal Tomcik, Cuong Tran-Manh, Xiang Zhou, Nicholas Dickel, Bilgesu Safak Tümerdem, Alexander Kreuter, Sven-Niklas Burmann, Signe Vedel Borchert, Rizwan Iqbal Hussain, Jonas Hallén, Jörg Klingelhöfer, Meik Kunz, and Jörg H. W. Distler

• 2023 January: Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis. Christopher P Denton, Shiwen Xu, Fenge Zhang, Rory H Maclean, Kristina E N Clark, Signe Borchert, Rizwan I Hussain, Jörg Klingelhöfer, Jonas Hallén, Voon H Ong

CAL103

• 2016 June: Innate sensing of oxidation-specific epitopes in health and disease. Christoph J. Binder, Nikolina Papac-Milicevic and Joseph L. Witztum